These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10170092)

  • 1. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada.
    Vandergrift M; Kanavos P
    Health Policy; 1997 Sep; 41(3):241-60. PubMed ID: 10170092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical policies in Canada: another example of federal-provincial discord.
    Anis AH
    CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

  • 6. Reimbursement for new health technologies. Breakthrough pharmaceuticals as a 20th century challenge.
    Glynn D
    Pharmacoeconomics; 2000; 18 Suppl 1():59-67. PubMed ID: 11151310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Myth of the Free Market for Pharmaceuticals.
    Conti RM; Frank RG; Cutler DM
    N Engl J Med; 2024 Apr; 390(16):1448-1450. PubMed ID: 38647106
    [No Abstract]   [Full Text] [Related]  

  • 8. The Chinese medicines market: moving towards a market system?
    Huttin C
    Health Policy; 1994 Sep; 29(3):247-59. PubMed ID: 10138727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in pricing and drug reimbursement in France.
    Pelc A; Castan JP
    Pharmacoeconomics; 1994; 6 Suppl 1():28-35. PubMed ID: 10155583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Policy in Latvia.
    Silins J; Szkultecka-Dębek M
    Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.
    Morgan SG; Thomson PA; Daw JR; Friesen MK
    Health Policy; 2013 Oct; 112(3):248-54. PubMed ID: 23809914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical pricing conundrum: time to get rid of it?
    Garattini L; Padula A
    Eur J Health Econ; 2018 Nov; 19(8):1035-1038. PubMed ID: 30030646
    [No Abstract]   [Full Text] [Related]  

  • 14. The emerging government requirement for economic evaluation of pharmaceuticals.
    Drummond M
    Pharmacoeconomics; 1994; 6 Suppl 1():42-50. PubMed ID: 10155586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2018 Dec; 2018():1-31. PubMed ID: 30695849
    [No Abstract]   [Full Text] [Related]  

  • 17. Financing pharmaceuticals in transition economies.
    Kanavos P
    Croat Med J; 1999 Jun; 40(2):244-59. PubMed ID: 10234068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian hopes for low-cost drugs dashed.
    Kondro W
    Lancet; 1998 Jan; 351(9099):350. PubMed ID: 9652632
    [No Abstract]   [Full Text] [Related]  

  • 19. The last decade of Italian pharmaceutical policy: instability or consolidation?
    Fattore G; Jommi C
    Pharmacoeconomics; 2008; 26(1):5-15. PubMed ID: 18088155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential stifling effects of pharmaco-economics and regulatory policies.
    Data JL
    Am J Cardiol; 1998 Apr; 81(8A):34F-35F. PubMed ID: 9604904
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.